Navigation Links
Gloucester Pharmaceuticals Reports on Romidepsin and Erlotinib,Combination in Non-Small Cell Lung Cancer Presented at American,Association of Cancer Research Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 18, 2007 - Gloucester Pharmaceuticals, Inc., an oncology focused biopharmaceutical company, announced today that encouraging data from a preclinical study examining the combination of romidepsin and erlotinib in non-small cell lung cancer (NSCLC) cell lines derived from human cancer patients were presented at the American Association of Cancer Research Meeting annual meeting taking place in Los Angles, CA. The study was co-authored by Wei Zhang, Ph.D., Michael Peyton, Ph.D., John D. Minna, M.D., Adi F. Gazdar, M.D. and Eugene P. Frenkel, M.D., all of the Hamon Center for Therapeutic Oncology Research at University of Texas Southwestern Medical Center.

In an oral presentation entitled "Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines" Dr. Zhang showed data from a preclinical study designed to examine the effect of the histone deacetylase (HDAC) inhibitor romidepsin in combination with the tyrosine kinase inhibitor (TKI) erlotinib in NSCLC. In the in vitro arm of the study, 22 NSCLC cell lines were treated with either romidepsin, erlotinib or romidepsin and erlotinib together. For the in vivo arm of the study H1299 xenografts were inoculated subcutaneously into nude mice. The developing tumors were treated with either romidepsin, erlotinib or romidepsin and erlotinib together.

In her conclusions Dr. Zhang reported that romidepsin synergistically enhanced erlotinib sensitivity in wild type NSCLC cell lines by induction of profound apoptosis. This synergy was also shown in the nude mice xenografts but was not observed in epidermal growth factor (EGFR) mutant cell lines.

"The data from this study are very promising and suggest that combining romidepsin with TKIs such as erlotinib may enhance the clinical activity in the non-EGFR mutant patient population, which is thought to be approx
'"/>




Page: 1 2 3

Related medicine technology :

1. Gloucester Pharmaceuticals Reports Positive Interim Phase II Data on Romidepsin for T-Cell Lymphomas at the 2007 American Society of Clinical Oncology Annual Meeting
2. Gloucester Pharmaceuticals Receives Fast Track Designation for Romidepsin in Peripheral T-Cell Lymphoma
3. Gloucester Pharmaceuticals Announces Multiple Presentations of Preclinical Romidepsin Data at American Association of Cancer Research Annual Meeting
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
11. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
Post Your Comments:
(Date:10/20/2014)... 20, 2014 Valeritas, Inc., a leader in ... with Type 2 diabetes, announced today that it has ... The award was presented October 16 th at ... Ohio . The Cardinal Health ... variety of metrics specifically targeted at the importance of ...
(Date:10/20/2014)... , Oct. 20, 2014 Pharmaceutic Labs ... facility in Albany, NY for ... The company meets and/or exceeds the FDA standards for ... 21 CFR Part 211. The 10,000 ... highest levels of quality assurance and quality control. The ...
(Date:10/19/2014)... , Oct. 20, 2014 CTI BioPharma Corp. ... will report its third quarter 2014 financial results on ... U.S. financial markets. Following the announcement, members of the ... discuss the results and provide a general corporate update ... the event can be obtained as follows: ...
Breaking Medicine Technology:Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2
... Anlit Advanced Nutrition Supplements , an ... for children, will present new and innovative products at ... 2012 in Geneva, Switzerland. Anlit will showcase new ... at Stand 3500. The company will present, among others, ...
... 2012  Luminex Corporation (NASDAQ: LMNX ) today announced ...  Financial and operating highlights include the following: , ... increase over the first quarter of 2011 , First ... over the first quarter of 2011 , First quarter ...
Cached Medicine Technology:Anlit to Present New Dietary Supplements for Children at Vitafoods Europe 2012 2Luminex Corporation Reports First Quarter 2012 Results 2Luminex Corporation Reports First Quarter 2012 Results 3Luminex Corporation Reports First Quarter 2012 Results 4Luminex Corporation Reports First Quarter 2012 Results 5Luminex Corporation Reports First Quarter 2012 Results 6Luminex Corporation Reports First Quarter 2012 Results 7Luminex Corporation Reports First Quarter 2012 Results 8
(Date:10/20/2014)... hc1.com today announced the launch of ... enables healthcare organizations of all sizes to immediately ... management (“CRM”) solution. , Designed from the ground ... healthcare industry, the hc1 Healthcare Relationship Cloud™ personalizes ... combining healthcare CRM, HIPAA-compliant collaboration, and real-time analytics ...
(Date:10/20/2014)... October 20, 2014 Principle Business Enterprises, ... pride in manufacturing top-of-the-line absorbent products. The company ... its most popular brand, Tranquility® Premium Protection absorbent products. ... new website, gave its packaging a new look, and ... brand message to the public. , The new website, ...
(Date:10/20/2014)... Succeed is proud to announce that they ranked ... the Every Body Walk! campaign by Kaiser Permanente. ... encourages workers to be more active outside of the workplace. ... at the end of September, was a friendly competition between ... Participating companies gave their staff pedometers and each day, ...
(Date:10/20/2014)... October 20, 2014 Unveiled at the Sept. ... Direction Scorecard conservatively estimates member hospital ROI on membership dues ... dues, The Center provides $12.50 in value to member hospitals. ... Value – Member Dues)/Member Dues. , “This is the ... number and we think the methodology is really sound,” said ...
(Date:10/20/2014)... October 20, 2014 Do you ever ... Here comes a wonderful app Metassessor for teachers, specialists ... company helped its client “Intervention Development LLC” to ... app is designed for iOS 4.3 or later and ... app is optimized for iPhone 5. It is now ...
Breaking Medicine News(10 mins):Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:Tranquility® Premium Protection Incontinence Products Releases New Logo and Website 2Health News:Succeed Management Solutions, LLC Competes in Walking Challenge and Achieves 12th Place in Portland 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3
... with full dedication. Same is the case in the lab ... world the first cancer vaccine. // ,The landmark day ... Drug Administration approved the vaccine, called Gardasil. This vaccine for cervical ... own words, "It's a researcher's dream … to see something that ...
... Clinical Nutrition says that the poor health and lifestyle of ... the society in its grip //. In a study of ... passed the habit to their sons and grandsons. ... Taiwan say that men who chewed betel nuts had children ...
... its focus from the curative mode of healthcare to ... Welfare Anbumani Ramadoss said here Friday //. ... for Hepatitis B and Japanese Encephalitis. We are switching ... after dedicating the Diarrhoeal Disease Research and Control Centre ...
... India as free from the dreaded rinderpest infection - an ... ,'This recognition of India as free from rinderpest ... disease to be officially recognised by Office Internationale des Epizooties ... in a statement Friday. ,'This freedom from one ...
... has said practising yoga, pranayam and meditation will help youths ... ,'Youths crave for something different and it is our ... he said while interacting with reporters last evening at Tapobhoomi, ... here., ,Ravi Shankar appealed to the youths to take ...
... Nationwide protests witnessed last month against the government's plan ... were a creation //of the media, Union Health Minister ... (to the proposal) came from the media,' he told ... percent reservation for the other backward classes (OBCs) in ...
Cached Medicine News:Health News:Govt to Shift its Focus From Curative to Preventive Mode of Healthcare 2Health News:India Declared Free of Rinderpest Cattle Infection 2
A lytic reagent manufactured for the simultaneous quantitative determinations of hemoglobin and white blood cells. Streck-Lysing Agent III is for use on the Abbott CELL-DYN® 1400 and 1600. The sh...
Streck-Diluent CD is a balanced electrolyte solution manufactured specifically for use as a diluent for blood cell counting and sizing on the Abbott CELL-DYN® 1800....
Streck-Detergent IIIA is a balanced electrolyte solution for use as a rinsing and hemoglobin blanking diluent. It is manufactured specifically for use on the Abbott CELL-DYN® 1700 and 1800. The s...
... hematology control for the Abbott CELL-DYN 3000, ... for the five-part white cell differential, as ... CELL-DYN 1600 and 1700. Open-vial stability is ... days. Para 12 Plus is packaged in ...
Medicine Products: